Navigation Links
Three Molecular Triggers Threaten Leukemia Patients

odel, where alternative molecular pathways help cancer survive the targeting of one pathway by a drug, is common in cancer, an accompanying editorial in Blood notes.

"This compensatory ability suggests that the use of single "targeted" agents may be suboptimal, a concept that, unfortunately is all too well supported by clinical experience in all malignancies and has broad implications for the entire field of cancer therapeutics," writes Judith Karp, M.D., of the Sidney Kimmel Cancer Center at Johns Hopkins.

"We need to listen carefully to the authors' eloquent plea for a new paradigm in drug development, namely the testing of multiple investigational agents in ways that target complementary molecules and attack the malignant phenotype from multiple angles," Karp concludes.

AML occurs when abnormal blood cells rapidly build up in the bone marrow, interfering with the production of normal blood cells. While chemotherapy often places the disease in remission, it usually comes back. Only about 20 percent of patients are cured with chemotherapy, and another 10 percent are successfully treated with bone marrow transplants.

One of the great successes of cancer treatment has been development of targeted therapy for chronic myelogenous leukemia (CML). The drug Gleevec and its successors inhibit one aberrant protein, increasing the median 5-year survival of CML patients from 50 percent to 90 percent. For AML, that approach won't work. "AML is more complicated, with multiple means of activation," Kornblau says.

The research team looked at activation of three components, one from each pathway, in the leukemic blasts found in newly diagnosed patients. Activation of each component - PKCa, pERK2 and pAKT - had an adverse effect on the patient's prospects that was independent of other traditional prognostic factors. Their cumulative impact was greater than simply adding their individual effects would suggest, the research
'"/>




Page: 1 2 3

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Nobel Prize for Medicine shared by Three scientists
3. Three Tropical Parasites Genetic Code Unravelled
4. The Future Pattern Of Weight Gain Is Laid As Early As Three Years Of Age
5. Smoking Increases The Risk Of Heart Disease By Three Times
6. Three Sisters Have One Baby and Make History
7. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
8. Three More Bird Flu Cases Reported By China
9. Three meals daily Keeps Keralas elderly Healthy
10. Three dimensional structure of apolipoprotein revealed
11. Delhi Witnessed 34 Meningitis Deaths In Three Months
Post Your Comments:
(Date:8/29/2008)...l., Aug. 29 /PRNewswire-FirstCall/ -- Landauer, In...irectors declared a regular,quarterly cash dividen...cal,2008. The dividend will be paid on October 3, ...008., About Landauer, Landauer is the leading pr...ional and environmental radiation exposure. For mo...
(Date:8/29/2008)... AMD presents Telemedicine Encounter Mana... State delegations as a possible solution to natio... N.Chelmsford, MA (PRWEB) August 29, 2008 -- If ...by the speakers at the Democratic National Convent...esolve our national health care issues., , ,Our De...
(Date:8/28/2008)...with person with dementia led to daytime tiredness...ug. 28 (HealthDay News) -- Older adults who live w...omeone with dementia have significantly worse slee..., The study compared 31 caregivers and 102 nonc...3 minutes less per night than non-caregivers and t...
(Date:8/28/2008)...f., Aug. 28 /PRNewswire-FirstCall/ -- ISTA Pharmac...t will present at the Thomas Weisel,Partners Healt...rsday,September 4, 2008 at the Four Seasons Hotel...tive Officer, Vicente Anido, Jr.,Ph.D., will prov...ical,progress. To access the live audio broadcast ...
Breaking Medicine News(10 mins):Health News:AMD Global Telemedicine Inc. Invited to Attend Democratic National Convention 2Health News:Older Caregivers Prone to Worse Sleep Patterns 2
Plump Infants Getting Obese Later In Life In More Cases
...ound that there is no link whatsoever between brea...atins or lipid lowering drugs //to control the sam...October 24 issue of Archives of Internal Medicine,... article says that although some evidence has been...
... likely to invoke the compulsory licensing (CL) pr...tic drug //firms to produce and stockpile Swiss dr...combating the global threat against the most dread...ers the government to issue CL without receipt of ...
...ial lung disease (ILD) comprises a large, heteroge...rized by diffuse infiltrates, restrictive lung dis...mortality and morbidity. ILD presents enormous dia...ial diagnosis includes more than 100 conditions in...
Other Medicine News:Health News:A New Diagnostic Approach To Pediatric Interstitial Lung Disease 2
(Date:8/28/2008)... to collaborate on studies of immunosuppression ...diated immunity, COLUMBIA, Md., Aug. 28 /PRNewswi...n distributor, Sun Woo Biotech, is delighted to be...enter trial of the ImmuKnow assay,for cell-mediate...tutions,in the Republic of Korea," stated Brad Ste...
(Date:8/28/2008)... /- Intercell AG (VSE: ICLL) today,an...s initiated a Phase II,clinical trial of V710, an ...hylococcus aureus (S. aureus) infections. This ran...s to evaluate the safety and immunogenicity of,the...ey disease on,hemodialysis. This trial start follo...
(Date:8/27/2008)...in Parts of Bucks, Delaware, Montgomery,Philadelp...e-USNewswire/ -- After encouraging,results followi...tment of,Environmental Protection will continue it...st the mosquito-borne West Nile virus., Targeted ....m. and,midnight in portions of Bucks, Delaware, M...
(Date:8/27/2008)..., melphalan and prednisone arm demonstrated a, si... complete response -, CAMBRIDGE, Mass., Aug. 27 /...pany today announced the publication of results fr... trial in this week,s edition of the,New England J...nt survival,benefit and a 30 percent complete remi...
Breaking Medicine Technology:Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 2Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 3Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 2Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 3DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6State of Arkansas Department of Human Services Division of Medical Services Selects U S Care Management for High Risk Obstetrics Health Management P 6752 1State of Arkansas Department of Human Services Division of Medical Services Selects U S Care Management for High Risk Obstetrics Health Management P 6752 2State of Arkansas Department of Human Services Division of Medical Services Selects U S Care Management for High Risk Obstetrics Health Management P 6752 3State of Arkansas Department of Human Services Division of Medical Services Selects U S Care Management for High Risk Obstetrics Health Management P 6752 4CardioMag Announces Results of 2006 Annual Shareholders Meeting and Board Meeting 1885 1CardioMag Announces Results of 2006 Annual Shareholders Meeting and Board Meeting 1885 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 1881 1Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 1881 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 1881 3Penn researchers find monkeys able to fend off AIDS like symptoms with enhanced HIV vaccine 1293 1Penn researchers find monkeys able to fend off AIDS like symptoms with enhanced HIV vaccine 1293 2
...ncer Conference, NORTH HOLLYWOOD, Calif., and CHIC...al Myeloma Foundation (IMF)-supporting research,an...eloma patients,families, researchers and physicia...e 3 multi- national clinical trial shows the,combi...obability of,survival by 41%. The follow-up study ...
...ity Support Development of Panzem(R),NCD as a Comb...ILLE, Md., June 05, 2007 /PRNewswire-FirstCall/ --...company developing,therapeutics for the treatment ... presentation of results of a single-agent Phase 2...lioblastoma,multiforme (GBM). The data were presen...
Other Medicine Technology:Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma 2Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 2Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 3Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 4
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
Medicine Products: